ES2276623B1 - Nuevos adenovirus recombinantes de replicacion condicionada (crad). - Google Patents

Nuevos adenovirus recombinantes de replicacion condicionada (crad). Download PDF

Info

Publication number: ES2276623B1
Authority: ES; Spain
Prior art keywords: gene; baselineskip; recombinant adenovirus; promoter; cells
Prior art date: 2005-12-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn - After Issue

Application number

ES200503047A

Other languages

English (en)

Spanish (es)

Other versions

ES2276623A1 (es

Inventor

Ruben Hernandez Alcoceba

Sergia Bortolanza

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Proyecto de Biomedicina CIMA SL

Original Assignee

Proyecto de Biomedicina CIMA SL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-12

Filing date

2005-12-12

Publication date

2008-06-01

2005-12-12 Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL

2005-12-12 Priority to ES200503047A priority Critical patent/ES2276623B1/es

2006-12-07 Priority to PCT/ES2006/000676 priority patent/WO2007068772A1/fr

2007-06-16 Publication of ES2276623A1 publication Critical patent/ES2276623A1/es

2008-06-01 Application granted granted Critical

2008-06-01 Publication of ES2276623B1 publication Critical patent/ES2276623B1/es

2025-12-12 Anticipated expiration legal-status Critical

Status Withdrawn - After Issue legal-status Critical Current

Links

241000701161 unidentified adenovirus Species 0.000 title claims abstract description 87
230000010076 replication Effects 0.000 title claims abstract description 27
230000001143 conditioned effect Effects 0.000 title claims abstract description 8
102100038710 Capping protein-inhibiting regulator of actin dynamics Human genes 0.000 title abstract 2
101000957909 Homo sapiens Capping protein-inhibiting regulator of actin dynamics Proteins 0.000 title abstract 2
108090000623 proteins and genes Proteins 0.000 claims abstract description 104
206010021143 Hypoxia Diseases 0.000 claims abstract description 50
230000007954 hypoxia Effects 0.000 claims abstract description 40
238000012217 deletion Methods 0.000 claims abstract description 29
230000037430 deletion Effects 0.000 claims abstract description 29
238000000034 method Methods 0.000 claims abstract description 13
108091027981 Response element Proteins 0.000 claims abstract description 12
239000000203 mixture Substances 0.000 claims abstract description 11
108060001084 Luciferase Proteins 0.000 claims description 24
230000014509 gene expression Effects 0.000 claims description 22
239000005089 Luciferase Substances 0.000 claims description 19
108010065805 Interleukin-12 Proteins 0.000 claims description 12
108700008625 Reporter Genes Proteins 0.000 claims description 9
101710138750 Transcription factor E2F1 Proteins 0.000 claims description 8
230000004044 response Effects 0.000 claims description 7
230000001225 therapeutic effect Effects 0.000 claims description 6
108020004440 Thymidine kinase Proteins 0.000 claims description 5
238000000338 in vitro Methods 0.000 claims description 5
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 1
102000058223 human VEGFA Human genes 0.000 claims 1
230000008569 process Effects 0.000 abstract description 3
101150066038 E4 gene Proteins 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 97
241000700605 Viruses Species 0.000 description 68
239000013612 plasmid Substances 0.000 description 40
206010028980 Neoplasm Diseases 0.000 description 30
239000012634 fragment Substances 0.000 description 23
108020004414 DNA Proteins 0.000 description 22
108090000790 Enzymes Proteins 0.000 description 20
230000000120 cytopathologic effect Effects 0.000 description 20
230000000694 effects Effects 0.000 description 20
102000004190 Enzymes Human genes 0.000 description 19
210000004881 tumor cell Anatomy 0.000 description 19
230000003612 virological effect Effects 0.000 description 16
230000007959 normoxia Effects 0.000 description 13
230000000174 oncolytic effect Effects 0.000 description 13
238000001415 gene therapy Methods 0.000 description 12
208000015181 infectious disease Diseases 0.000 description 12
230000003362 replicative effect Effects 0.000 description 12
230000029812 viral genome replication Effects 0.000 description 12
241001135569 Human adenovirus 5 Species 0.000 description 10
108091034117 Oligonucleotide Proteins 0.000 description 10
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
101100440985 Danio rerio crad gene Proteins 0.000 description 9
101100440987 Mus musculus Cracd gene Proteins 0.000 description 9
101100467905 Mus musculus Rdh16 gene Proteins 0.000 description 9
238000003752 polymerase chain reaction Methods 0.000 description 9
102000013462 Interleukin-12 Human genes 0.000 description 8
230000002238 attenuated effect Effects 0.000 description 8
210000002950 fibroblast Anatomy 0.000 description 8
238000013518 transcription Methods 0.000 description 8
230000035897 transcription Effects 0.000 description 8
108700005077 Viral Genes Proteins 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
229910052760 oxygen Inorganic materials 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
239000013598 vector Substances 0.000 description 7
230000008901 benefit Effects 0.000 description 6
238000010276 construction Methods 0.000 description 6
230000029087 digestion Effects 0.000 description 6
230000001146 hypoxic effect Effects 0.000 description 6
230000001939 inductive effect Effects 0.000 description 6
239000002245 particle Substances 0.000 description 6
101710199711 Early E1A protein Proteins 0.000 description 5
230000004913 activation Effects 0.000 description 5
230000000259 anti-tumor effect Effects 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
238000013461 design Methods 0.000 description 5
230000001524 infective effect Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000001301 oxygen Substances 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 4
230000034994 death Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
108700039691 Genetic Promoter Regions Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
230000018199 S phase Effects 0.000 description 3
102000006601 Thymidine Kinase Human genes 0.000 description 3
108700019146 Transgenes Proteins 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
230000003321 amplification Effects 0.000 description 3
230000003263 anti-adenoviral effect Effects 0.000 description 3
230000001772 anti-angiogenic effect Effects 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000013078 crystal Substances 0.000 description 3
230000002950 deficient Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 3
229960002963 ganciclovir Drugs 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000003364 immunohistochemistry Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
238000010186 staining Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
108091026890 Coding region Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
201000000582 Retinoblastoma Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000007710 freezing Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
102000050313 human E2F1 Human genes 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000006698 induction Effects 0.000 description 2
229940117681 interleukin-12 Drugs 0.000 description 2
230000002601 intratumoral effect Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
244000309459 oncolytic virus Species 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
238000010257 thawing Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
108700026220 vif Genes Proteins 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
102100027211 Albumin Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
241000070918 Cima Species 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
101710114676 E1B 55 kDa protein Proteins 0.000 description 1
102000015699 E2F1 Transcription Factor Human genes 0.000 description 1
108010063774 E2F1 Transcription Factor Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
206010019695 Hepatic neoplasm Diseases 0.000 description 1
102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
241000598171 Human adenovirus sp. Species 0.000 description 1
108700002232 Immediate-Early Genes Proteins 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101100364971 Mus musculus Scai gene Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
101710132596 Protein E4 Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
101000687509 Rattus norvegicus Prolactin Proteins 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
108050002653 Retinoblastoma protein Proteins 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
108700025695 Suppressor Genes Proteins 0.000 description 1
108010017842 Telomerase Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
241000021375 Xenogenes Species 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
108010006025 bovine growth hormone Proteins 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052792 caesium Inorganic materials 0.000 description 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
238000013043 cell viability test Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000008029 eradication Effects 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
102000015694 estrogen receptors Human genes 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
230000008826 genomic mutation Effects 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011503 in vivo imaging Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
238000003670 luciferase enzyme activity assay Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
238000012379 oncolytic virotherapy Methods 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
238000002600 positron emission tomography Methods 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000022983 regulation of cell cycle Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000009331 sowing Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
239000000717 tumor promoter Substances 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000006648 viral gene expression Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
238000000316 virotherapy Methods 0.000 description 1
238000012800 visualization Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ES200503047A 2005-12-12 2005-12-12 Nuevos adenovirus recombinantes de replicacion condicionada (crad). Withdrawn - After Issue ES2276623B1 (es)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
ES200503047A ES2276623B1 (es)	2005-12-12	2005-12-12	Nuevos adenovirus recombinantes de replicacion condicionada (crad).
PCT/ES2006/000676 WO2007068772A1 (fr)	2005-12-12	2006-12-07	Nouveaux adenovirus recombinants de replications conditionnee (crad)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES200503047A ES2276623B1 (es)	2005-12-12	2005-12-12	Nuevos adenovirus recombinantes de replicacion condicionada (crad).

Publications (2)

Publication Number	Publication Date
ES2276623A1 ES2276623A1 (es)	2007-06-16
ES2276623B1 true ES2276623B1 (es)	2008-06-01

Family

ID=38162589

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES200503047A Withdrawn - After Issue ES2276623B1 (es)	2005-12-12	2005-12-12	Nuevos adenovirus recombinantes de replicacion condicionada (crad).

Country Status (2)

Country	Link
ES (1)	ES2276623B1 (fr)
WO (1)	WO2007068772A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9345787B2 (en)	2008-12-22	2016-05-24	Targovax Oy	Adenoviral vectors and methods and uses related thereto
ES2612889T3 (es) *	2008-12-22	2017-05-19	Targovax Oy	Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos
CN102174479B (zh) *	2011-03-02	2013-04-03	北京锤特生物科技有限公司	靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用
US12421502B2 (en)	2013-04-18	2025-09-23	Tilt Biotherapeutics Oy	Enhanced adoptive cell therapy
WO2014170389A1 (fr) *	2013-04-18	2014-10-23	Tilt Biotherapeutics Oy	Thérapie cellulaire adoptive améliorée

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004031357A2 (fr) *	2002-10-01	2004-04-15	Duke University	Therapie tumorale ciblee utilisant des vecteurs d'adenovirus recombinants a replication selective dans les regions hypoxiques des tumeurs
US6900049B2 (en) *	1998-09-10	2005-05-31	Cell Genesys, Inc.	Adenovirus vectors containing cell status-specific response elements and methods of use thereof

2005
- 2005-12-12 ES ES200503047A patent/ES2276623B1/es not_active Withdrawn - After Issue
2006
- 2006-12-07 WO PCT/ES2006/000676 patent/WO2007068772A1/fr not_active Ceased

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6900049B2 (en) *	1998-09-10	2005-05-31	Cell Genesys, Inc.	Adenovirus vectors containing cell status-specific response elements and methods of use thereof
WO2004031357A2 (fr) *	2002-10-01	2004-04-15	Duke University	Therapie tumorale ciblee utilisant des vecteurs d'adenovirus recombinants a replication selective dans les regions hypoxiques des tumeurs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CUEVAS Y. et al. Specific Oncolytic Effect of a New Hypoxia- Inducible Factor-Dependent Replicative Adenovirus on von Hippel- Lindau-Defective Renal Cell Carcinomas. Cancer Research, 15.10.2003, vol. 63, nº 20, páginas 6877-84. *
JOHNSON, L. et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent systemic antitumor agents. Cancer Cell, mayo 2002, vol. 1, nº 4, páginas 325-37. *

Also Published As

Publication number	Publication date
ES2276623A1 (es)	2007-06-16
WO2007068772A1 (fr)	2007-06-21

Publication	Publication Date	Title
AU2019216631B2 (en)	2021-04-29	Enhanced adoptive cell therapy
ES2557812T3 (es)	2016-01-28	Mutantes de E1a y E1b de adenovirus selectivos de tumor
ES2358204T3 (es)	2011-05-06	Adenovirus quiméricos para uso en el tratamiento del cáncer.
Everts et al.	2005	Replication-selective oncolytic viruses in the treatment of cancer
ES2466415T3 (es)	2014-06-10	Construcción de recombinante de adenovirus oncolítico que expresa específicamente el factor inmunomodulador GM-CSF en células tumorales y usos del mismo
JP5075839B2 (ja)	2012-11-21	癌の処置のための腫瘍崩壊性アデノウイルス
RU2711371C2 (ru)	2020-01-16	Аденовирус, содержащий альбумин-связывающий участок
ES2210081T3 (es)	2004-07-01	Utilizacion de los marcos de lectura de la region e4 para la mejora de la expresion de genes.
US20090270485A1 (en)	2009-10-29	Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
ES2230820T3 (es)	2005-05-01	Procedimiento de inactivacion de virus envueltos en una preparacion virica de adenovirus.
JP2020521471A (ja)	2020-07-27	導入遺伝子を保持する組換えアデノウイルス
JP2011200234A (ja)	2011-10-13	新規アデノウイルス、それをコードする核酸及びその使用
JP5584393B2 (ja)	2014-09-03	動物細胞における多剤耐性を逆転させる方法
JP4361708B2 (ja)	2009-11-11	複製−コンピテント抗癌ベクター
Del Papa et al.	2019	An oncolytic adenovirus vector expressing p14 FAST protein induces widespread syncytium formation and reduces tumor growth rate in vivo
ES2276623B1 (es)	2008-06-01	Nuevos adenovirus recombinantes de replicacion condicionada (crad).
Del Papa et al.	2021	Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic
US7829329B2 (en)	2010-11-09	Adenoviral vectors for treating disease
CN115038455B (zh)	2024-11-29	复制增强的溶瘤腺病毒
ES2325303T3 (es)	2009-09-01	Vectores adenoviricos lanzadera con e1b suprimida.
ES3018628T3 (es)	2025-05-16	Adenovirus oncolíticos no humanos y usos de los mismos
ES2367240T3 (es)	2011-10-31	Vectores adenovíricos para le tratamiento de enfermedades.
CN1705740B (zh)	2013-07-24	具有反向基因表达的腺病毒及其应用
Clarkin	2018	Enhancing oncolytic adenovirus vector efficacy through co-expression of the p14 fusion-associated small transmembrane protein and adenovirus death protein
KR20050060175A (ko)	2005-06-22	저산소하에서 작동되는 프로모터를 가진 암 용해성아데노바이러스 및 이를 포함하는 항암조성물

Legal Events

Date	Code	Title	Description
2007-06-16	EC2A	Search report published	Date of ref document: 20070616 Kind code of ref document: A1
2008-06-01	FG2A	Definitive protection	Ref document number: 2276623B1 Country of ref document: ES
2009-03-16	FA2A	Application withdrawn	Effective date: 20090226

Date

Code

Title

Description

2007-06-16

EC2A

Search report published

Date of ref document: 20070616

Kind code of ref document: A1

2008-06-01

FG2A

Definitive protection

Ref document number: 2276623B1

Country of ref document: ES

2009-03-16

FA2A

Application withdrawn

Effective date: 20090226